- 現金殖利率: N/A、總殖利率: 0、5年平均現金配發率: N/A
- 要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
- 股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)
EPS YoY | 現金股利 YoY | 股票股利 YoY | 現金配發率 YoY | 股票配發率 YoY | 全部配發率 YoY | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
2023 (10) | 0.11 | 57.14 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
2022 (9) | 0.07 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
2021 (8) | -0.71 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
2020 (7) | -5.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
2019 (6) | -2.92 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
2018 (5) | -1.23 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
2017 (4) | -1.22 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
2016 (3) | -2.89 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
EPS QoQ YoY | 本業EPS QoQ YoY | 累計EPS QoQ YoY | |||||||
---|---|---|---|---|---|---|---|---|---|
24Q3 (20) | 0.04 | 136.36 | 100.0 | 0.02 | 116.67 | 200.0 | -0.05 | 44.44 | -155.56 |
24Q2 (19) | -0.11 | -650.0 | -375.0 | -0.12 | -20.0 | -340.0 | -0.09 | -550.0 | -228.57 |
24Q1 (18) | 0.02 | 0.0 | 0.0 | -0.10 | -600.0 | -300.0 | 0.02 | -81.82 | 0.0 |
23Q4 (17) | 0.02 | 0.0 | 0 | 0.02 | 200.0 | -60.0 | 0.11 | 22.22 | 57.14 |
23Q3 (16) | 0.02 | -50.0 | 100.0 | -0.02 | -140.0 | 60.0 | 0.09 | 28.57 | 28.57 |
23Q2 (15) | 0.04 | 100.0 | 300.0 | 0.05 | 0.0 | -70.59 | 0.07 | 250.0 | 16.67 |
23Q1 (14) | 0.02 | 0 | -60.0 | 0.05 | 0.0 | 350.0 | 0.02 | -71.43 | -60.0 |
22Q4 (13) | 0.00 | -100.0 | -100.0 | 0.05 | 200.0 | 103.11 | 0.07 | 0.0 | 109.86 |
22Q3 (12) | 0.01 | 0.0 | 101.12 | -0.05 | -129.41 | 93.42 | 0.07 | 16.67 | 103.0 |
22Q2 (11) | 0.01 | -80.0 | 100.88 | 0.17 | 950.0 | 116.67 | 0.06 | 20.0 | 104.17 |
22Q1 (10) | 0.05 | -96.91 | 116.13 | -0.02 | 98.76 | 86.67 | 0.05 | 107.04 | 116.13 |
21Q4 (9) | 1.62 | 282.02 | 239.66 | -1.61 | -111.84 | -250.0 | -0.71 | 69.53 | 85.8 |
21Q3 (8) | -0.89 | 21.93 | 29.37 | -0.76 | 25.49 | -28.81 | -2.33 | -61.81 | 39.32 |
21Q2 (7) | -1.14 | -267.74 | -15.15 | -1.02 | -580.0 | 11.3 | -1.44 | -364.52 | 20.44 |
21Q1 (6) | -0.31 | 73.28 | 62.65 | -0.15 | 67.39 | 83.33 | -0.31 | 93.8 | 62.65 |
20Q4 (5) | -1.16 | 7.94 | -58.9 | -0.46 | 22.03 | 24.59 | -5.00 | -30.21 | -71.23 |
20Q3 (4) | -1.26 | -27.27 | 0.0 | -0.59 | 48.7 | 0.0 | -3.84 | -112.15 | 0.0 |
20Q2 (3) | -0.99 | -19.28 | 0.0 | -1.15 | -27.78 | 0.0 | -1.81 | -118.07 | 0.0 |
20Q1 (2) | -0.83 | -13.7 | 0.0 | -0.90 | -47.54 | 0.0 | -0.83 | 71.58 | 0.0 |
19Q4 (1) | -0.73 | 0.0 | 0.0 | -0.61 | 0.0 | 0.0 | -2.92 | 0.0 | 0.0 |
年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
---|---|---|---|---|---|---|---|---|---|---|
2024/10 | 0.27 | -31.31 | -19.22 | 3.12 | -1.11 | 1.0 | N/A | - | ||
2024/9 | 0.4 | 18.44 | 23.12 | 2.85 | 1.05 | 0.99 | 0.28 | - | ||
2024/8 | 0.33 | 27.77 | 13.95 | 2.45 | -1.78 | 0.93 | 0.3 | - | ||
2024/7 | 0.26 | -20.93 | -7.16 | 2.12 | -3.88 | 0.94 | 0.3 | - | ||
2024/6 | 0.33 | -3.43 | -19.96 | 1.86 | -3.4 | 0.96 | 0.33 | - | ||
2024/5 | 0.34 | 21.16 | 11.8 | 1.53 | 1.14 | 0.96 | 0.33 | - | ||
2024/4 | 0.28 | -14.56 | 9.17 | 1.18 | -1.58 | 0.88 | 0.36 | - | ||
2024/3 | 0.33 | 25.7 | -23.38 | 0.9 | -4.54 | 0.9 | 0.37 | - | ||
2024/2 | 0.26 | -13.15 | 8.29 | 0.57 | 11.47 | 0.96 | 0.34 | - | ||
2024/1 | 0.3 | -23.47 | 14.38 | 0.3 | 14.38 | 1.08 | 0.31 | - | ||
2023/12 | 0.4 | 5.13 | -31.54 | 3.93 | 3.55 | 1.11 | 0.29 | - | ||
2023/11 | 0.38 | 11.93 | -3.73 | 3.54 | 9.87 | 1.04 | 0.31 | - | ||
2023/10 | 0.34 | 4.7 | 22.3 | 3.16 | 11.76 | 0.95 | 0.34 | - | ||
2023/9 | 0.32 | 9.61 | -11.07 | 2.82 | 10.62 | 0.9 | 0.4 | - | ||
2023/8 | 0.29 | 4.09 | -21.54 | 2.5 | 14.22 | 0.99 | 0.36 | - | ||
2023/7 | 0.28 | -31.84 | -8.67 | 2.21 | 21.61 | 1.0 | 0.36 | - | ||
2023/6 | 0.41 | 34.9 | 17.82 | 1.92 | 27.83 | 0.98 | 0.32 | - | ||
2023/5 | 0.31 | 18.31 | 27.19 | 1.51 | 30.88 | 1.0 | 0.31 | - | ||
2023/4 | 0.26 | -40.04 | -5.74 | 1.2 | 31.86 | 0.94 | 0.33 | - | ||
2023/3 | 0.43 | 77.69 | 88.31 | 0.94 | 48.14 | 0.94 | 0.38 | 主要係人臉辨識大型專案驗收所致 | ||
2023/2 | 0.24 | -8.27 | 12.15 | 0.51 | 25.4 | 1.09 | 0.33 | - | ||
2023/1 | 0.27 | -54.2 | 40.64 | 0.27 | 40.64 | 1.24 | 0.29 | - | ||
2022/12 | 0.58 | 47.85 | 25.8 | 3.8 | 8.23 | 1.25 | 0.28 | - | ||
2022/11 | 0.39 | 42.2 | 8.64 | 3.22 | 5.57 | 1.03 | 0.34 | - | ||
2022/10 | 0.28 | -23.86 | 13.58 | 2.83 | 5.16 | 1.01 | 0.35 | - | ||
2022/9 | 0.36 | -3.29 | 40.21 | 2.55 | 4.32 | 1.05 | 0.38 | - | ||
2022/8 | 0.37 | 21.18 | 158.5 | 2.19 | 0.08 | 1.04 | 0.39 | 主要係臺灣及香港疫情趨緩致業績上升 | ||
2022/7 | 0.31 | -12.06 | 32.94 | 1.81 | -11.16 | 0.9 | 0.44 | - | ||
2022/6 | 0.35 | 45.63 | 89.97 | 1.5 | -16.81 | 0.87 | 0.46 | 主要係大型人臉辨識專案完成驗收轉列收入 | ||
2022/5 | 0.24 | -12.32 | 22.38 | 1.15 | -29.0 | 0.75 | 0.54 | - | ||
2022/4 | 0.28 | 19.77 | -18.8 | 0.91 | -36.11 | 0.72 | 0.55 | - | ||
2022/3 | 0.23 | 5.82 | -39.89 | 0.64 | -41.51 | 0.64 | 0.53 | - | ||
2022/2 | 0.22 | 15.03 | -23.48 | 0.41 | -42.38 | 0.87 | 0.39 | - | ||
2022/1 | 0.19 | -59.03 | -55.13 | 0.19 | -55.13 | 1.01 | 0.34 | 主要係大陸市場受疫情影響 | ||
2021/12 | 0.46 | 27.68 | -22.37 | 3.51 | -14.89 | 1.06 | 0.26 | - | ||
2021/11 | 0.36 | 48.67 | -35.21 | 3.05 | -13.63 | 0.86 | 0.32 | - | ||
2021/10 | 0.24 | -6.02 | -44.85 | 2.69 | -9.59 | 0.65 | 0.43 | - | ||
2021/9 | 0.26 | 78.28 | -22.64 | 2.44 | -3.46 | 0.64 | 1.07 | - | ||
2021/8 | 0.14 | -37.67 | -61.82 | 2.19 | -0.54 | 0.56 | 1.21 | 主要係大陸市場客戶受疫情影響,造成營收減少 | ||
2021/7 | 0.23 | 25.65 | -34.02 | 1.98 | 9.12 | 0.61 | 1.11 | - | ||
2021/6 | 0.19 | -6.18 | -39.26 | 1.81 | 23.36 | 0.72 | 1.07 | 主要大陸市場客戶受疫情影響需求,造成營收減少 | ||
2021/5 | 0.2 | -41.83 | -22.51 | 1.62 | 39.78 | 0.92 | 0.84 | - | ||
2021/4 | 0.34 | -11.33 | 71.72 | 1.43 | 57.27 | 1.01 | 0.77 | 去年減少主要係大陸市場受疫情影響 | ||
2021/3 | 0.38 | 34.72 | 33.14 | 1.09 | 53.25 | 1.09 | 0.48 | 主要係人臉辨識專案完成驗收轉列收入 | ||
2021/2 | 0.28 | -32.54 | 53.48 | 0.7 | 66.93 | 1.3 | 0.4 | 去年減少主要係大陸市場受疫情影響 | ||
2021/1 | 0.42 | -29.12 | 77.42 | 0.42 | 77.42 | 1.57 | 0.33 | 主要係Face8人臉辨識系統相關系列產品成長 | ||
2020/12 | 0.59 | 6.57 | 110.87 | 4.12 | -34.21 | 1.59 | 0.31 | 主要係大型指標人臉辨識專案完成驗收轉列收入 | ||
2020/11 | 0.56 | 26.55 | 23.7 | 3.53 | -41.04 | 1.33 | 0.38 | - | ||
2020/10 | 0.44 | 31.81 | -36.95 | 2.97 | -46.3 | 1.15 | 0.43 | - | ||
2020/9 | 0.33 | -12.0 | -47.71 | 2.53 | -47.65 | 1.07 | 0.56 | - | ||
2020/8 | 0.38 | 7.7 | -41.21 | 2.2 | -47.65 | 1.04 | 0.58 | - | ||
2020/7 | 0.35 | 15.66 | -25.26 | 1.82 | -48.82 | 0.91 | 0.66 | - | ||
2020/6 | 0.3 | 19.68 | -17.41 | 1.47 | -52.42 | 0.76 | 0.79 | 主要受新冠肺炎疫情影響 | ||
2020/5 | 0.25 | 28.9 | -37.85 | 1.16 | -57.18 | 0.74 | 0.81 | 主要受到新冠肺炎疫情影響 | ||
2020/4 | 0.2 | -31.25 | -64.05 | 0.91 | -60.62 | 0.67 | 0.9 | 主要受到新冠肺炎疫情影響 | ||
2020/3 | 0.29 | 55.3 | -51.62 | 0.71 | -59.55 | 0.71 | 0.8 | 主要受到全球肺炎疫情影響 | ||
2020/2 | 0.19 | -22.02 | -41.57 | 0.42 | -63.6 | 0.7 | 0.81 | 主要受到肺炎疫情影響,中國暫緩開工、封城隔離,以及全球為防疫減少外出 | ||
2020/1 | 0.24 | -15.76 | -71.87 | 0.24 | -71.87 | 0.97 | 0.59 | 主要係因大陸市場淡季影響 | ||
2019/12 | 0.28 | -37.47 | -51.86 | 6.27 | -16.96 | 0.0 | N/A | 主要係大陸市場銷售下滑 | ||
2019/11 | 0.45 | -35.5 | -37.97 | 5.99 | -14.02 | 0.0 | N/A | - |